Human T-cell leukemia virus type I (HTLV-I) is the first human retrovirus and causes adult T-cell leukemia/lymphoma (ATL). Constitutive activation of nuclear factor-kappa B (NF-kappa B) in the leukemic cells is essential for their growth and survival. Thus, NF-kappa B inhibitors have been attracting attention as a potential strategy to treat ATL. Recently, the field of retrovirus research has been stimulated by the discovery of an innate host defense factor, APOBEC3, against the retroviruses. HTLV-I is relatively resistant to the antiviral effects of APOBEC3. To clarify the resistance of HTLV-I against APOBEC3 might contribute to the design of effective therapeutic approaches.

中文翻译：

---

当前预防人类 T 细胞白血病病毒 i 型感染的主题：NF-κ B 抑制剂和 APOBEC3。


人类 T 细胞白血病病毒 I 型 (HTLV-I) 是第一种人类逆转录病毒，可导致成人 T 细胞白血病/淋巴瘤 (ATL)。白血病细胞中核因子 kappa B (NF-kappa B) 的组成型激活对其生长和生存至关重要。因此，NF-κB抑制剂作为治疗ATL的潜在策略已引起人们的关注。最近，针对逆转录病毒的先天宿主防御因子 APOBEC3 的发现刺激了逆转录病毒研究领域。 HTLV-I 对 APOBEC3 的抗病毒作用相对抵抗。阐明 HTLV-I 对 APOBEC3 的耐药性可能有助于设计有效的治疗方法。